MAMA · Mama's Creations, Inc. · Stock research

Current Thesis

Mama's Creations is a microcap deli prepared-foods roll-up whose growth is genuinely accelerating: Q1 FY2027 (reported 2026-06-08) posted revenue +49.7% YoY and adjusted EBITDA +71%. The problem is the entry, not the story. At $19.94 (2026-06-26) the stock is pinned to its 52-week high ($20.18), trades above the entire published analyst target band, and has no company catalyst until the ~September print. The platform is compounding; the chart is extended. A buy at the highs is paying up for a thin-float name with no near-term fuel.

Bullish and bearish views on Mama's Creations, Inc.

The model's bull view on Mama's Creations, Inc. (MAMA), in brief: Revenue $52.8M in Q1 FY2027 (2026-06-08), +49.7% YoY from $35.3M; adjusted EBITDA $4.9M, +71.2%; EPS $0.05 beat the $0.03 consensus. The bear view: Valuation leaves no error margin: ~132x trailing P/E and an ~$811M cap on a roughly $210M-revenue protein manufacturer. Both cases follow in full.

Bull Case

• Revenue $52.8M in Q1 FY2027 (2026-06-08), +49.7% YoY from $35.3M; adjusted EBITDA $4.9M, +71.2%; EPS $0.05 beat the $0.03 consensus. The beat-and-raise cadence under CEO Adam Michaels is intact.
• Crown I Enterprises (acquired 2025-09-02 from Sysco, $17.5M all-cash, ~$56M annual revenue at roughly 0.3x sales) lifted the sales base ~40% an accretive bolt-on that demonstrates ongoing M&A optionality.
• Distribution is broadening across Costco, Walmart, Target and Food Lion; the company cited organic Costco strength in Q1 even while lapping a ~$10M digital Costco MVM from the prior-year quarter.
• Margin-recovery runway: on the 2026-06-08 call management reiterated a mid-to-high-20s% gross-margin target, framing the current 23.6% as depressed by transient new-packaging-technology startup costs.
• Clean balance sheet $24.4M cash against $5.1M debt at Q1 FY2027 funds further automation and acquisitions without obvious dilution pressure.
• Small, uniformly constructive sell-side: 5–6 analysts at a Strong Buy consensus as of June 2026.

Bear Case

• Valuation leaves no error margin: ~132x trailing P/E and an ~$811M cap on a roughly $210M-revenue protein manufacturer. The multiple already prices flawless execution.
• Gross margin fell to 23.6% in Q1 FY2027 from 26.1% a year earlier. If the "transient" startup inefficiencies bleed into the ~September Q2 print, the margin-expansion leg of the thesis cracks.
• Price ($19.94, 2026-06-26) sits above the full analyst PT band (~$12 low / ~$15 median / ~$18–19 high) much of the sell-side re-rate fuel that drives small-cap momentum is already spent.
• Thin liquidity: ~1.7M shares average daily volume on a microcap that gaps both directions and is hard to exit in size.
• Growth is partly acquisition-fueled (Crown I, Bay Shore); reported headline growth can mask organic deceleration as Crown laps into the comps later in FY2027.
• Beef, poultry and labor are direct, uncontrolled input-cost risks sitting on the same margin line management is trying to expand.

Setup & Price Structure

• $19.94 close 2026-06-26 (after-hours ~$20.02), pressed against the 52-week high of $20.18; the 52-week low is $7.88, so the name has roughly 2.5x'd off the bottom.
• Momentum is stretched RSI near 77, extended above the moving averages and the recent push is post-earnings drift (the catalyst was 2026-06-08), not a fresh trigger.
• Structurally the stock cleared the ~$16–18 consolidation shelf into new-high territory; that shelf is now first support with the rising trend intact above it.
• Average volume ~1.7M shares means fills near the highs carry real slippage risk.
• This is an extended entry, not a base. The clean re-entry is a pullback to the breakout shelf / rising 20-EMA that then prints a higher low not a purchase at the 52-week high.

Catalyst Calendar (next 30 days)

• No company-specific catalyst inside 30 days. Next earnings (Q2 FY2027) estimated ~2026-09-15, outside the window which removes near-term binary earnings risk but also means no scheduled fuel for the next leg.
• Episodic, undated: incremental retailer-win or new-item-launch press releases (Costco / Walmart / Target / Food Lion), and any bolt-on M&A announcement management has openly telegraphed continued acquisition appetite.
• Possible summer investor-conference appearances (undated) typically low-impact.

What Would Change Our Mind

• Bullish setup confirmation: a pullback into the $16–18 breakout shelf that holds and forms a higher low converts this chase into a setup worth sizing.
• Thesis break: a weekly close below $16.50 surrenders the post-Q1 breakout structure and the accelerating-growth bid, leaving an expensive microcap mean-reverting toward its moving averages.
• A Q2 FY2027 print (~September) showing gross margin failing to recover toward the mid-20s% or organic growth decelerating below ~20% would break the margin/compounding leg even before the price confirms it.

Correlation Notes

• Idiosyncratic small-cap consumer staples with low correlation to the AI/semiconductor complex that drives most active momentum books useful diversification, but no theme cluster to confirm the move.
• Carries small-cap risk-appetite beta (reads against the Russell 2000) and protein-commodity sensitivity (beef, poultry) on the margin line.
• No tight listed peer; loosely framed against branded and private-label deli/prepared-foods categories (Hormel, Conagra) but trades on its own roll-up story rather than the group.